Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.

Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE.

Haematologica. 2011 Mar;96(3):450-3. doi: 10.3324/haematol.2010.033191. Epub 2010 Dec 15.

2.

Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.

Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE.

Br J Haematol. 2013 Jan;160(1):70-9. doi: 10.1111/bjh.12099. Epub 2012 Nov 1.

PMID:
23116358
3.

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC.

Blood. 2010 Mar 11;115(10):2003-7. doi: 10.1182/blood-2009-09-245381. Epub 2010 Jan 8.

4.

The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.

Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, Pop IV, Popp RA.

Ann Hematol. 2010 Oct;89(10):979-83. doi: 10.1007/s00277-010-0960-y. Epub 2010 Apr 27.

PMID:
20422415
5.

The JAK2 V617F mutation in patients with cerebral venous thrombosis.

Passamonti SM, Biguzzi E, Cazzola M, Franchi F, Gianniello F, Bucciarelli P, Pietra D, Mannucci PM, Martinelli I.

J Thromb Haemost. 2012 Jun;10(6):998-1003. doi: 10.1111/j.1538-7836.2012.04719.x.

6.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

7.

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M.

Cancer. 2006 Nov 1;107(9):2206-11.

8.

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.

Yoo EH, Jang JH, Park KJ, Gwak GY, Kim HJ, Kim SH, Kim DK.

Int J Lab Hematol. 2011 Oct;33(5):471-6. doi: 10.1111/j.1751-553X.2011.01308.x. Epub 2011 Mar 24.

PMID:
21435189
10.

Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.

Tondeur S, Boutruche S, Biron-Andréani C, Schved JF.

Thromb Haemost. 2009 Apr;101(4):787-9. No abstract available.

PMID:
19350131
11.

[The quantitative evaluation of mutation V617F of gene JAK2 under chronic myeloproliferative diseases].

Abdullaeva AO, Glinshchikova OA, Suslova SA, Shadieva NKh, Kolosova LIu, Meshcheriakova LM, Vakhrusheva MV, Sudarikov AB.

Klin Lab Diagn. 2012 Jul;(7):24-8. Russian.

PMID:
22988798
12.

[Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].

Zhang Y, Li L, Nie L, Yu Y, Yang YH, Zhang ZQ, Yang L, Xu SC, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2008 Feb;29(2):105-9. Chinese.

PMID:
18681311
13.

JAK2 V617F: implications for thrombosis in myeloproliferative diseases.

Hexner EO.

Curr Opin Hematol. 2007 Sep;14(5):450-4. Review.

PMID:
17934351
14.

Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.

Colaizzo D, Amitrano L, Tiscia GL, Iannaccone L, Gallone A, Grandone E, Guardascione MA, Margaglione M.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):459-62. doi: 10.1097/MBC.0b013e3283049662.

PMID:
18600100
15.

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party.

Thromb Haemost. 2009 Mar;101(3):547-51.

PMID:
19277418
16.

What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?

Lopes da Silva R, Ribeiro P, Lourenço A, Santos SC, Santos M, Costa I, de Sousa AB.

Lab Hematol. 2011 Mar;17(1):12-6. doi: 10.1532/LH96.10018.

PMID:
21421540
17.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

18.

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.

Sazawal S, Bajaj J, Chikkara S, Jain S, Bhargava R, Mahapatra M, Saxena R.

Indian J Med Res. 2010 Oct;132:423-7.

19.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
20.

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.

Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.

Coll Antropol. 2012 Sep;36(3):859-65.

PMID:
23213945

Supplemental Content

Support Center